{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Cjc-1295",
    "short_name": "CJC-1295",
    "aliases": [
      "cjc",
      "CJC-1295 (no DAC)",
      "CJC-1295 DAC",
      "GHRH analog"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Investigational peptide discussed as a GHRH analog affecting GH/IGF signaling. Not an FDA-approved therapeutic drug."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "CJC-1295 is not an approved therapeutic drug. Human evidence exists for GH/IGF changes in controlled settings, but long-term safety and outcome evidence for enhancement use is limited."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 7,
      "severity": "high",
      "likelihood": "possible",
      "evidence_grade": "human_interventional",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Manipulating GH/IGF axis has systemic downstream effects (glucose handling, edema, blood pressure, sleep). Human studies show endocrine effects; however, long-term outcomes and safety in non-medical enhancement contexts are uncertain. Adolescents are higher consequence risk due to developing endocrine setpoints.",
      "risk_score": 7
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "moderate",
          "evidence_grade": "human_interventional",
          "text": "CJC-1295 is a growth hormone releasing hormone (GHRH) analog discussed for increasing growth hormone and IGF-1 signaling. Controlled human research has reported endocrine changes, but long-term clinical outcomes and safety for enhancement use remain uncertain.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [
        {
          "text": "These are the most common real-world reasons people look into this peptide, plus the context that tends to matter most (quality, expectations, and safety).",
          "title": "Use cases (real-world)"
        },
        {
          "text": "sleep and recovery interest tied to GH physiology (real-world reports vary)"
        },
        {
          "text": "body composition interest in training communities (outcomes vary)"
        },
        {
          "text": "sometimes discussed alongside other GH-axis peptides (stacking culture)"
        }
      ],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "varies",
          "unit": "study-dependent",
          "min": null,
          "max": null,
          "frequency": "varies",
          "duration": "varies",
          "population_group": "general",
          "notes": "Descriptive only. This app does not provide protocols. Not instructions.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "developmental_risk_block": [
        {
          "title": "Developmental / Adolescent risk",
          "population_group": "adolescent",
          "confidence": "moderate",
          "evidence_grade": "unknown",
          "text": "Because CJC-1295 targets GH/IGF signaling, adolescents and still-developing endocrine systems should treat uncertainty as a meaningful risk. Long-term setpoint changes are not well characterized.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "interaction_summary": [
        {
          "text": "Interactions here are category flags — they’re meant to help you ask better questions and avoid obvious conflicts. They are not a dosing guide.",
          "title": "Interaction summary"
        },
        {
          "text": "Drug-class flags to review:"
        },
        {
          "text": "endocrine-axis-modulation-context"
        },
        {
          "text": "If you’re on cardiovascular, anticoagulant/antiplatelet, serotonergic, or immunomodulating meds/supplements, treat uncertainty as a reason to slow down and verify with a clinician."
        }
      ],
      "current_outlook_bullets": [
        "a growth hormone releasing hormone (GHRH) analog discussed for increasing growth hormone and IGF-1 signaling",
        "controlled human research has reported endocrine changes, but long-term clinical outcomes and safety for enhancement use remain uncertain",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "CJC-1295 increases growth hormone and IGF-1 in healthy adults (human interventional study)",
        "source_type": "pubmed",
        "source_id": "16352683",
        "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/",
        "published_date": "2006-01-01",
        "evidence_grade": "human_interventional",
        "notes": "Interventional human research reporting GH/IGF-1 changes. Does not establish long-term enhancement outcomes or safety in non-medical use contexts.",
        "year": 2006
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for CJC-1295",
        "detail": "Added GHRH analog entry with human endocrine evidence and strong uncertainty framing; flagged developmental risk due to endocrine setpoint concerns.",
        "evidence_refs": [
          "E1"
        ]
      }
    ],
    "meta": {
      "appears_in_blends": [
        "cjc-ipamorelin"
      ]
    },
    "topics": {
      "primary": [
        "topic_muscle_recovery",
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "cjc-1295"
  },
  "canonical_name": "Cjc-1295",
  "interactions": {
    "drug_classes": [
      "endocrine-axis-modulation-context"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "CJC-1295 is a GHRH analog discussed to stimulate growth-hormone signaling. It can meaningfully affect endocrine physiology, appetite, fluid balance, and glucose control.",
    "benefits": [
      "sleep and recovery interest tied to GH physiology (real-world reports vary)",
      "body composition interest in training communities (outcomes vary)",
      "sometimes discussed alongside other GH-axis peptides (stacking culture)"
    ],
    "side_effects_common": [
      "flushing or warmth",
      "water retention or swelling",
      "headache"
    ],
    "side_effects_serious": [
      "worsening glucose control in susceptible users",
      "severe swelling, palpitations, or fainting"
    ],
    "who_should_be_cautious": [
      "people with diabetes, prediabetes, or metabolic syndrome",
      "people with active cancer or a high cancer-risk history (growth signaling context)",
      "pregnant or breastfeeding individuals",
      "adolescents (endocrine-axis impact plus long-term uncertainty)"
    ],
    "schema_version": "practical_block_v1"
  }
}
